CCR5突变或治疗性阻断与肝纤维化生物标志物改善相关
本研究评估CCR5自然突变(delta-32)或药物阻断对HIV-1患者肝纤维化生物标志物的影响。在MHCS队列中,携带delta-32等位基因者的ELF指数随时间显著下降(P = .043);接受CCR5/CCR2拮抗剂cenicriviroc治疗的患者也出现ELF指数显著下降,而依非韦伦或低剂量cenicriviroc组未观察到此现象。提示CCR5突变或阻断可调节HIV-1感染者的肝纤维化。
要点
- CCR5 delta-32突变与HIV/HCV共感染者ELF指数显著下降相关。
- CCR5/CCR2拮抗剂cenicriviroc治疗与ELF指数显著下降相关。
- 依非韦伦或低剂量cenicriviroc未观察到ELF指数显著下降。
核心结论
- CCR5突变或CCR5/CCR2阻断与HIV-1感染者肝纤维化生物标志物改善相关,提示肝纤维化可被调控。
研究设计与样本
- 研究纳入两个队列:多中心血友病队列研究(MHCS)中HIV/HCV共感染且携带CCR5 delta-32等位基因者,以及接受CCR5/CCR2拮抗剂cenicriviroc治疗的HIV-1感染队列。
- 采用增强肝纤维化(ELF)指数,并对照HCV/HIV及HCV患者肝组织学验证其与纤维化分期的强相关性。
主要发现
- 在MHCS患者和cenicriviroc治疗患者中,CCR5突变或阻断均与ELF指数显著下降相关。
- 携带delta-32等位基因者连续样本的ELF指数下降速率显著高于CCR5野生型患者(P = .043)。
- 接受依非韦伦或100 mg低剂量cenicriviroc的对照受试者未观察到此现象。
临床怎么用
- 对于HIV-1合并肝纤维化风险患者,CCR5/CCR2阻断可能作为改善肝纤维化的潜在策略,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The C-C chemokine receptor Type 5 (CCR5) is a key receptor for human immunodeficiency virus type 1 (HIV-1) entry into T-cells and a variant allele, CCR5 delta-32, is associated with decreased viral replication and disease progression. Active HIV-1 replication is highly associated with accelerated rates of hepatic fibrosis. We postulated that CCR5 plays a role in the development of hepatic fibrosis and evaluated the longitudinal effect of natural or drug-induced CCR5 mutation and blockade on biomarkers of liver fibrosis in HIV-1 patients. METHODS: To accomplish this goal, we examined 2 distinct cohorts. First, we evaluated fibrosis markers in the Multicenter Hemophilia Cohort Studies (MHCS), which included subjects with HIV and hepatitis C virus (HCV) coinfection with the CCR5 delta-32 allele. We also evaluated an HIV-1 infected cohort that was treated with a dual CCR5/CCR2 antagonist, cenicriviroc. The enhanced liver fibrosis (ELF) index was validated against liver histology obtained from HCV/HIV and HCV patients and demonstrated strong correlation with fibrosis stage. RESULTS: In both the MHCS patients and patients treated with cenicriviroc, CCR5 mutation or blockade was associated with a significant decrease in the ELF index. Among the patients with the delta-32 allele, the ELF index rate significantly decreased in sequential samples as compared to CCR5 wild-type patients (P = .043). This was not observed in control subjects treated with efavirenz nor with a lower dose of 100 mg cenicriviroc. CONCLUSION: These findings suggest that hepatic fibrosis in HIV-1 infected patients can be modulated by the mutation of CCR5 and/or use of CCR5/CCR2 blockade agents. CLINICAL TRIALS REGISTRATION: NCT01338883.
引用
- Sherman KE, Abdel-Hameed E, Rouster SD, et al. Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade. Clin Infect Dis. 2019. PMID: 30239650. doi:10.1093/cid/ciy807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。